FDA Section 5 \u2022 cited verbatim

Guanfacine - Warnings and Precautions

The following warnings and precautions are taken directly from the US FDA-approved drug label for Guanfacine. This is the same information dispensing pharmacists read.

5 WARNINGS AND PRECAUTIONS • Hypotension, bradycardia, syncope: Titrate slowly and monitor vital signs frequently in patients at risk for hypotension, heart block, bradycardia, syncope, cardiovascular disease, vascular disease, cerebrovascular disease or chronic renal failure.

Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy.

Avoid concomitant use of drugs with additive effects unless clinically indicated.

Advise patients to avoid becoming dehydrated or overheated . • Sedation and somnolence: Occur commonly with guanfacine extended-release tablets.

Consider the potential for additive sedative effects with CNS depressant drugs.

Caution patients against operating heavy equipment or driving until they know how they respond to guanfacine extended-release tablets • Cardiac Conduction Abnormalities: May worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs.

Titrate slowly and monitor vital signs frequently . • Rebound Hypertension: Abrupt discontinuation of guanfacine extended-release tablets can lead to clinically significant and persistent rebound hypertension.

Subsequent hypertensive encephalopathy was also reported.

To minimize the risk of rebound hypertension upon discontinuation, the total daily dose of guanfacine extended-release tablets should be tapered in decrements of no more than 1 mg every 3 to 7 days .

5.1 Hypotension, Bradycardia, and Syncope Treatment with guanfacine extended-release tablets can cause dose-dependent decreases in blood pressure and heart rate.

Decreases were less pronounced over time of treatment.

Orthostatic hypotension and syncope have been reported [see Adverse Reactions ] .

Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy.

Titrate guanfacine extended-release tablets slowly in patients with a history of hypotension, and those with underlying conditions that may be worsened by hypotension and bradycardia; e.g., heart block, bradycardia, cardiovascular disease, vascular disease, cerebrovascular disease, or chronic renal failure.

In patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration, advise patients to avoid becoming dehydrated or overheated.

Monitor blood pressure and heart rate, and adjust dosages accordingly in patients treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope.

5.2 Sedation and Somnolence Somnolence and sedation were commonly reported adverse reactions in clinical studies [see Adverse Reactions ] .

Before using guanfacine extended-release tablets with other centrally active depressants, consider the potential for additive sedative effects.

Caution patients against operating heavy equipment or driving until they know how they respond to treatment with guanfacine extended-release tablets .

Advise patients to avoid use with alcohol.

5.3 Cardiac Conduction Abnormalities The sympatholytic action of guanfacine extended-release tablets may worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs.

Titrate guanfacine extended-release tablets slowly and monitor vital signs frequently in patients with cardiac conduction abnormalities or patients concomitantly treated with other sympatholytic drugs.

5.4 Rebound Hypertension In post marketing experience, abrupt discontinuation of guanfacine extended-release tablets has resulted in clinically significant and persistent rebound hypertension above baseline levels and increases in heart rate.

Hypertensive encephalopathy has also been reported in association with rebound hypertension with both guanfacine extended-release tablets and immediate release guanfacine [see Adverse Reactions ] .

In these cases, high-dosage guanfacine was discontinued; concomitant stimulant use was also reported, which may potentially increase hypertensive response upon abrupt discontinuation of guanfacine.

Applies to YOU?

Some warnings apply only to specific age groups, health conditions, or other medicines. Ask GoDavaii AI to filter which of these 29+ warnings apply to your profile.

Ask Health AI \u2192